Compare Msci Inc (MSCI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Neurocrine Biosciences Inc — how do they compare? Msci Inc trades at $562 (market cap $40.84B), while Neurocrine Biosciences Inc trades at $156.86 (market cap $16.46B). The key difference: Msci Inc is far larger — about 2.5× Neurocrine Biosciences Inc's market cap, and Msci Inc pays a 1.46% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MSCI | NBIX | |
|---|---|---|
Market Cap | $40.84B | $16.46B |
Sector | Financials | Health |
52-Week High | $643.83 | $185.50 |
52-Week Low | $511.84 | $123.10 |
Enterprise Value | $47.00B | $16.48B |
Dividend Yield | 1.46% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
